Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | PLA2G4C | Q9UP65 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487516 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2FAAHPLA2G4B | |
| SCHEMBL2840059 | 0.84 | CES1 (0.52) | ALDH1A1MAPT | |
| SCHEMBL6261092 | 0.82 | ALDH1A1 (0.58) | ALDH1A1CNR1CNR2TRPV1 | |
| SCHEMBL12474184 | 0.82 | ALDH1A1 (0.58) | ALDH1A1CNR1CNR2TRPV1 | |
| SCHEMBL29286069 | 0.81 | LPAR1 (0.45) | FAAHTRPV1 | |
| SCHEMBL18545973 | 0.81 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2TRPV1 | |
| SCHEMBL18546028 | 0.81 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2TRPV1 | |
| SCHEMBL18546025 | 0.81 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2TRPV1 | |
| SCHEMBL18546023 | 0.81 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2TRPV1 | |
| SCHEMBL15054267 | 0.81 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009129385-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | ALDH1A1 4724/4885CNR1 3144/4885CNR2 2239/4885 |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | ALDH1A1 4724/4885CNR1 3144/4885CNR2 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.